GP training may ease long COVID burden
NCT ID NCT06082258
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This trial tests whether training general practitioners to better manage persistent symptoms after COVID-19 can improve patients' quality of life. Adults with at least two long COVID symptoms (like fatigue, breathlessness, or brain fog) lasting over two months will be enrolled. The study compares standard care to a program where GPs receive specialized training and are reimbursed for longer consultations. The main goal is to see if patients report better physical health after three months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
training and support intervention for general practitioners
What this could lead to
If effective, this approach could offer a practical way to improve quality of life for people with persistent post-COVID symptoms through better GP care.
What could go wrong
This is a relatively small, early-stage study focused on GP training rather than a direct treatment, so benefits may be modest or not generalizable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-ACUTE COVID-19 SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
DAC 75
Paris, 75013, France
-
DAC 92
Suresnes, 92150, France
-
DAC 93
Saint-Denis, 93200, France
-
Paris Est (CPTS 12e et 20e)
Paris, 75012, France
-
Paris Nord (CPTS 10e)
Paris, 75010, France
-
Paris Ouest (CPTS 15e)
Paris, 75015, France
-
Paris Sud (CPTS 13-14e)
Paris, 75013, France